NCT00413972View on ClinicalTrials.gov

Effects of Vytorin Versus Placebo in Subjects With Primary Hypercholesterolemia (Study P04420)

PHASE3CompletedINTERVENTIONAL
Enrollment

392

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

November 30, 2006

Study Completion Date

November 30, 2006

Conditions
Hypercholesterolemia
Interventions
DRUG

ezetimibe with simvastatin

Ezetimibe 10 mg with Simvastatin 10 mg once daily for a total of eight weeks

DRUG

Ezetimibe with Simvastatin

Ezetimibe 10 mg with Simvastatin 20 mg once daily for a total of eight weeks

DRUG

Ezetimibe with Simvastatin

Ezetimibe 10 mg with Simvastatin 40 mg once daily for a total of eight weeks

DRUG

Placebo

Placebo once daily for a total of eight weeks

Sponsors

Collaborators (1)

Schering-Plough
All Listed Sponsors
collaborator

Schering-Plough

INDUSTRY

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Organon and Co

INDUSTRY

NCT00413972 - Effects of Vytorin Versus Placebo in Subjects With Primary Hypercholesterolemia (Study P04420) | Biotech Hunter | Biotech Hunter